ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

Forgot password
  • Home
  • About
  • News
  • FDA approves new combo HCV drug (ledipasvir and sofosbuvir) for genotype1: IFN and RBV sparing

FDA approves new combo HCV drug (ledipasvir and sofosbuvir) for genotype1: IFN and RBV sparing

13 Oct 2014 11:37 AM | Christopher McCoy

The U.S. Food and Drug Administration approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.  It is the first approved regimen that is interferon or ribavirin sparing.

For more information, please visit: Harvoni.


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
(331) 248-7888 • sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software